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Systemic sclerosis (SSc) is a connective tissue disease characterized by tissue fibrosis, 
vasculopathy, and autoimmunity. Although the exact pathogenetic mechanisms behind 
SSc remain to be fully elucidated, a great deal of evidence suggests the existence of an 
unbalanced ratio between the effector and regulatory arms of the immune system. With 
regard to the T regulatory (Treg) compartment, we observed that CD8+ Treg subsets 
display functional defects in SSc-affected patients. Since CD127 down-modulation and 
CD39 upregulation have been observed on Treg subsets, the phenotypic expression of 
these molecules was analyzed on the CD8+CD28− Treg precursors and on CD8+ Treg 
cells generated in  vitro through interleukin-10 commitment. Immunophenotypic data 
from SSc patients were compared to those obtained from healthy subjects. The analyses 
performed on ex vivo-isolated CD8+CD28− Treg precursors did not show any significant 
differences in CD39 or CD127 expression as compared to values obtained from healthy 
donors. On the contrary, in  vitro-generated CD8+ Tregs obtained from SSc patients 
displayed reduced expression of the CD39 molecule as compared to controls. Moreover, 
the percentage of CD127+ cells was significantly higher in in  vitro-generated CD8+ 
Tregs from SSc patients compared to CD8+ Tregs obtained from healthy donors. Taken 
together, these findings may indicate an impairment of maturation processes affecting 
CD8+ Treg cells in SSc patients. This impairment of maturation involves phenotypic 
alterations that are mainly characterized by a deficient CD39 upregulation and a lack of 
down-modulation of the CD127 molecule.
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inTrODUcTiOn
Several subsets of T regulatory (Treg) lymphocytes with distinct phenotypes and mechanisms of 
action have been described among CD8+ T cells. As the CD4+ Treg counterpart, these cells play 
an important role in physiological and pathological conditions such as autoimmune, infectious, 
or neoplastic diseases (1, 2). In particular, our group has characterized a subset of CD8+ Treg 
lymphocytes that mediate suppression without antigen restriction. These CD8+ Treg cells origi-
nate from circulating CD8+CD28−CD127+CD39− T lymphocytes through in vitro conditioning 
with interleukin (IL)-2 and IL-10; therefore, they belong to the “peripherally induced” CD8+ Treg 
subpopulations (1, 3, 4). From a functional point of view, these non-antigen-specific CD8+ Tregs 
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inhibit both T cell proliferation and cellular cytotoxicity through 
the secretion of cytokines, mostly IL-10, and do not require direct 
cell-to-cell contact to mediate their inhibitory functions (1, 5, 6). 
Furthermore, we recently identified an additional regulatory 
mechanism involving the activity of CD39 ecto-nucleotidase (4), 
as already described for CD4+ Tregs. Finally, these cells share 
with CD4+ Treg the down-modulation of the CD127 molecule, 
so that their exact phenotype is CD8+CD28−CD127loCD39+ 
(3, 4, 7).
Systemic sclerosis (SSc) is a systemic connective tissue 
disease characterized by small vessel vasculopathy, immune 
alterations, and fibroblast dysfunction leading to diffuse tis-
sue fibrosis (8). Even though SSc pathogenesis is still largely 
elusive, autoimmunity seems to be implicated in disease devel-
opment as suggested by the presence of several abnormalities 
in humoral and cellular immunity (9). Concerning this latter 
point, alterations of the normal functional balance between 
pro-inflammatory subpopulations, in particular Th17, and Treg 
subpopulations have been demonstrated in patients affected by 
SSc (10–15).
With regard to the Treg compartment, we observed that 
both CD4+ and CD8+ Treg subsets show quantitative and 
functional defects in SSc patients (16). This is reminiscent 
of what we recently found studying CD8+ Tregs in primary 
biliary cirrhosis (PBC), an organ-specific, fibrotic autoimmune 
disease that share with SSc several pathogenetic mechanisms 
(17). In PBC, CD8+ Treg abnormalities seem to correlate 
with increased CD127 antigen expression and reduced CD39 
molecule expression. This observation is not surprising since 
CD127, the α-chain of the IL-7 receptor, is mainly expressed 
on effector cells and is physiologically down-modulated on Treg 
lymphocytes (18), while CD39 is a membrane-bound nucleo-
sidase whose activity has been correlated with Treg function 
(4, 7, 19).
Therefore, we decided to analyze CD127 and CD39 molecule 
expression in CD8+ Tregs derived from SSc patients in order to 
determine whether alterations affecting these two pathways could 
explain the functional impairment observed in the CD8+ Treg 
subpopulation.
MaTerials anD MeThODs
Patients and controls
Twenty-eight patients affected with SSc (mean age 64 ± 14 years, 
female/male ratio 3/1) were enrolled at the Division of Internal 
Medicine and Clinical Immunology of the Department of Internal 
Medicine, University of Genoa, after providing informed consent.
Diagnosis of SSc was made according to the American College 
of Rheumatology criteria (20). Enrolled patients were being 
treated with vasoactive (e.g., iloprost or dihydropyridine calcium 
channel blockers) but not with immunosuppressive drugs. Ten 
healthy subjects, age and sex matched with the SSc patients, were 
enrolled as controls.
The study was carried out in compliance with the Helsinki 
Declaration and was approved by the Ethics Committee of the 
San Martino Hospital in Genoa, Italy.
Monoclonal antibodies (mabs)
The following mAbs were used for immunostaining and analysis 
by flow cytometry (FACS): allophycocyanin (APC)-cyanin 7 
(Cy7) conjugated anti-CD4 (Clone RPA-T4), APC-conjugated 
anti-CD39 (Clone TU66), phycoerythrin-conjugated anti-CD127 
(Clone M21), PeCy7 conjugated anti-CD25 (Clone M-A251), flu-
orescein isothiocyanate-conjugated anti CD45RA (Clone HI100), 
Brilliant Violet 421-conjugated anti-CD8 (Clone RPA-T8), and 
Horizon V500-conjugated anti-CD3 (Clone UCHT1) [Becton 
Dickinson (BD) Biosciences]; PerCP-cyanin 5-conjugated anti-
CD28 (Clone CD28.2) (Biolegend). CD8+ T cells (1 × 106) were 
incubated with a mAb cocktail for 30  min at 4°C in the dark. 
After staining procedures, the samples were washed with PBS 
and stored at 4°C. The samples were acquired and analyzed by 
a FACSCanto flow cytometer II equipped with three lasers (BD 
Biosciences, San Josè, CA, USA) using the FACSDIVA software 
(BD Biosciences). Fluorescence minus one was used to properly 
interpret flow cytometry data.
Purification of cD8+ T lymphocytes
Peripheral blood mononuclear cells (PBMCs) were purified 
from the venous heparinized blood samples of healthy controls 
and SSc patients by centrifugation on Ficoll-Hypaque gradient 
(Biochrom AG, Berlin, Germany) for 30 min at 1,800 rpm. CD8+ 
T lymphocytes were isolated by sequential cycles of cell sorting 
on magnetic beads using microbeads conjugated with a mAb 
specific for the CD8 antigen (Dynal CD8 positive isolation kit, 
Invitrogen by Life Technologies Ltd., Paisley, UK) following the 
manufacturer’s instructions.
In Vitro generation of cD8 Tregs from the 
Peripheral Blood Precursors
CD8+ Tregs were generated as previously described (21). Briefly, 
purified CD8+ T lymphocytes (2 × 105 cells/well) resuspended 
in culture medium consisting of RPMI 1640 culture medium 
(Gibco by Life Technologies Ltd., Paisley, UK) added with 10% 
fetal calf serum (Invitrogen by Life Technologies Ltd., Paisley, 
UK) were incubated with 20 U/ml of IL-2 (Proleukin, Eurocetus, 
Amsterdam, The Netherlands) and 10 ng/ml of IL-10 (PeproTech, 
Rocky Hill, NJ, USA) in 96-well flat bottomed plates (Sardsted) 
at 37°C for 7  days. The regulatory activity and the membrane 
antigen study were performed on both freshly ex vivo-purified 
CD8+ T cells and on in vitro-generated CD8+ Tregs.
Proliferation suppression assay
The suppressive activity of Treg was evaluated by monitoring the 
inhibition of dye dilution in PBMC stained with carboxyfluores-
cein diacetate succinimidyl ester (CFDA-SE, 5  µM, Molecular 
Probes, Invitrogen).
Briefly, the PBMC-CFDA-SE+ were pulsed with the anti-
CD3 UCTH-1 mAb (5 µg/ml, BD Bioscience) and cultured for 
5 days in a 96-well U bottomed plate (1 × 105 cells/well) in the 
presence (or not) of ex vivo- or in vitro-generated CD8+ T lym-
phocytes (1 × 105 cells/well). Then, the samples were harvested, 
washed in PBS, and analyzed by flow cytometry. The dead cells 
were excluded from analysis by adding 7-aminoactinomycin D 
FigUre 1 | In vitro generation of cD8+ T regulatory (Treg) cell in 
healthy donors and systemic sclerosis (ssc) patients. The bars indicate 
the frequency of healthy donors (left bar) and SSc patients (right bar) showing 
normal (suppression activity ≥25%, white bars) or impaired (suppression 
activity <25%, black bars) CD8+ Treg function. Statistical analyses were 
performed by Fisher’s exact test.
FigUre 2 | cD39 expression on freshly isolated cD8+cD28− 
lymphocytes and in vitro-generated cD8+ T regulatory (Treg) cell. 
(a) Histograms showing the percentages of expression of the CD39 molecule 
on freshly isolated CD8+CD28− lymphocytes (T0) and on interleukin-10-
committed CD8+CD28−CD127− T cells (T7) from a representative healthy 
donor (left) and a representative systemic sclerosis (SSc) patient (right). 
(B) Mean percentages of CD39+CD8+CD28− Treg cells in healthy donors 
(black bar) and SSc patients (white bar). Statistical analyses were performed 
by Mann–Whitney test.
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(7-AAD) (BD Bioscience) prior to analysis. Suppression activity 
was expressed as the percentage reduction of the proliferation in 
the presence of CD8+ Treg lymphocytes compared to the levels 
of proliferation observed in control cultures of PBMCs cultured 
in the absence of Treg cells. A suppression activity ≥25% was 
considered significant. This threshold was chosen based on 
the results achieved in a large historical cohort of more than 
50 healthy subjects of both sexes with age ranging from 18 to 
87  years. In healthy donors, CD8+ Treg suppression activity 
never fell below 25%.
statistical analyses
Statistically significant differences between frequencies were 
analyzed by Fisher’s exact test. Statistically significant differences 
between mean values were analyzed by the Mann–Whitney 
test for non-parametric values. Differences were considered 
statistically significant when p <  0.05. Statistical analyses were 
performed using GraphPad Prism version 6.03 for Windows 
(GraphPad Software, San Diego, CA, USA).
resUlTs
altered generation of cD8 Tregs  
in ssc Patients
The suppressive activity of in  vitro-generated CD8+ Tregs 
obtained from SSc patients was analyzed in comparison with 
that of healthy donors. In vitro generation of CD8+ Tregs 
led to the differentiation of circulating CD8+ T cells into 
CD8+CD28−CD127−CD39+ T  lymphocytes mediating a 
suppressive activity ≥25% in suppression assays in 10 out of 10 
(100%) healthy donors. In contrast, impaired in vitro generation 
of CD8+ Tregs was observed in 1/3 of SSc patients since in vitro-
generated CD8+ Tregs from 10 out of 28 SSc patients failed 
to exert a suppressive activity above the 25% threshold. The 
differences between the frequencies of subjects showing ≥25% 
suppressive activity by their CD8+ Treg in healthy controls and 
SSc patients was statistically significant (p = 0.04) as assessed by 
Fisher’s exact test (Figure 1; Tables S1 and S2 in Supplementary 
Material).
cD39 expression on cD8+ Treg cells
Given that the expression of CD39 is related to the suppressive 
activity of both CD4 and CD8 Treg cells (4, 7), its expression was 
analyzed on freshly isolated CD8+CD28− (formally CD8+ Treg 
precursors) and on in vitro-generated CD8+ Treg cells from both 
SSc patients and healthy donors.
CD39 molecule was undetectable (with values below 
0.01% among the CD3+ T cell population) on freshly isolated 
CD8+CD28− lymphocytes obtained from both SSc patients and 
healthy controls at T0 (Figure  2A). Interestingly, while CD39 
expression was strongly upregulated in CD8+ Tregs generated 
from healthy subjects with respect to their circulating precur-
sor CD8+CD28− T cells, this increase was not observed in SSc 
patients. Indeed, CD39 expression was significantly lower in 
in vitro-generated CD8+ Tregs from SSc patients with respect to 
in vitro-generated CD8+ Tregs from healthy donors, as assessed 
by Mann–Whitney test (p = 0.0032; Figures 2A,B).
cD127 expression in cD8 Treg 
subpopulation
We previously observed that CD127 antigen down-modulation is 
strictly related to the correct functional maturation/generation of 
CD8+ Tregs: thus, we explored its expression on freshly isolated 
CD8+CD28− and on in vitro-generated CD8+ Tregs from SSc 
patients and healthy donors.
No differences in CD127 expression were observed on 
CD8+CD28− cells from the peripheral blood of SSc patients and 
healthy controls at T0 (Figures 3A,B). However, CD127 expres-
sion diminished on CD8+CD28− after IL10 commitment for 
Treg generation in healthy donors (p = 0.04), while it increased 
on the corresponding cells from SSc patients (p = 0.029) with 
respect to their circulating precursors (Figures 3A,B, analyses 
performed by Mann–Whitney test). Accordingly, the percent-
age of CD127+ T cells on CD8+CD28− T lymphocytes after 
in vitro CD8+ Treg generation was significantly higher in cells 
from SSc patients as compared to healthy subjects (p =  0.02, 
Figure 3A).
FigUre 4 | analysis of the suppression activity of cD8+ T regulatory 
(Treg) cell generated from systemic sclerosis (ssc) patients in relation 
to the expression patterns of cD39/cD127. The bars display the 
frequencies of SSc patients showing impaired (suppression activity <25%, 
left bar) or normal (suppression activity ≥25%, right bar) CD8+ Treg function 
in relation to the expression patterns of CD39/CD127 molecules  
(normal—white bars, abnormal—black bars). Statistical analyses were 
performed by Fisher’s exact test.
FigUre 3 | cD127 expression on freshly isolated cD8+cD28− 
lymphocytes and in vitro-generated cD8+ T regulatory (Treg) cell. 
(a) Mean percentages of CD127+ cells in freshly isolated CD8+CD28− 
lymphocytes (T0) and in vitro-generated CD8+ Treg (T7) in healthy donors 
(black bar) and systemic sclerosis (SSc) patients (white bar). (B) Histograms 
showing the percentages of expression of the CD127 molecule on freshly 
isolated CD8+CD28− lymphocytes (T0) and on interleukin-10-committed 
CD8+CD28− T cells (T7) from a representative healthy donor (left) and a 
representative SSc patient (right). Statistical analyses were performed by 
Mann–Whitney test.
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Collectively, our data envisage the dependence of abnormal 
CD8+ Treg function in SSc patients on their altered expression 
of CD39 and/or CD127 molecules. In order to find support to 
this pathogenic mechanism, the frequencies of SSc patients 
showing impaired (suppression activity <25%) or normal (sup-
pression activity ≥25%) CD8+ Treg function were related, by 
Fisher’s exact test analysis, to the existence, in the CD8+ Treg 
of each single patient, of an abnormal expression of CD39 and/
or CD127 molecules (considering as altered expression the 
downregulation of CD39 and the upregulation of CD127 with 
respect to the relative CD8+CD28− T cell precursors, respec-
tively). Figure  4 and Table  1 show that the frequency of SSc 
patients showing abnormal expression of CD39 and/or CD127 
molecules within patients with altered CD8+ Treg function was 
more than twice that observed in patients with normal CD8+ 
Treg activity. This observation highlights the strict relationship 
between altered CD39 and/or Cd127 expression and CD8+ Treg 
function.
DiscUssiOn
The results of our work show that (1) in vitro generation of CD8 
Treg lymphocytes may be altered in SSc patients, thus leading to 
impaired suppressor activity; (2) CD8 Tregs generated from SSc 
patients display reduced CD39 expression and increased CD127 
expression compared to CD8+ Tregs generated from healthy 
donors.
Systemic sclerosis is a chronic connective tissue disease 
characterized by diffuse tissue fibrosis, microangiopathy, and 
immune abnormalities. Although the cause of SSc is unknown, 
autoimmunity seems to play an important role in the pathogen-
esis of the disease. Support for this hypothesis includes the pres-
ence of autoantibodies, evidence of abnormalities in B and T cell 
compartments in both the circulation and the affected organs, 
altered levels of growth factors, chemokines and cytokines, 
and the potential clinical overlap with other clearly recognized 
autoimmune diseases such as systemic lupus erythematosus 
and rheumatoid arthritis (8, 17, 22, 23). Our group recently 
described the existence of an imbalance between effector and 
regulatory responses in SSc patients. In particular, we observed 
that an increased Th17 effector response is associated with 
defective T cell regulation involving quantitative and functional 
alterations in both CD4+CD25+ and CD8+ Treg subpopula-
tions (16). Furthermore, we recently described the qualitative 
defects affecting CD8+ Tregs in PBC, an organ-specific, fibrotic 
autoimmune disease. In this disease, CD8+ Treg functional 
abnormalities correlate with the defective expression of the 
CD39 molecule and the increased expression of the CD127 
antigen (17).
CD39 is a cell surface ecto-nucleotidase that hydrolyzes 
extracellular ATP or ADP to AMP. Additionally, in concert with 
CD73, another ecto-nucleotidase which dephosphorylates AMP, 
its activity leads to the production of adenosine. Furthermore, 
there is increasing evidence indicating that CD39 and puriner-
gic signaling alterations may be implicated in pathological 
conditions such as neoplastic and inflammatory diseases (24). 
Although the role of CD39 has been less investigated in CD8+ 
Tregs, our group recently reported that CD39 is expressed and 
involved in the activity of non-antigen-specific CD8+ Treg 
cells (4). Furthermore, we correlated the defective expression 
of CD39 molecules with the functional impairment of CD8+ 
Tregs generated from patients affected by PBC (17). Based on 
this, we explored the role of CD39 in SSc. Interestingly, CD8+ 
Tregs generated from healthy subjects exhibit a significant 
upregulation of CD39 expression with respect to their precursor 
CD8+CD28− T cells, while this phenomenon was not observed 
in CD8+ Tregs generated from SSc patients. Considering the 
important role of CD39 for Treg regulatory activity, CD39 
expression defects could explain, at least in part, the functional 
impairment observed in CD8+ Tregs generated from SSc 
patients.
TaBle 1 | Percentage of cD127 and cD39 expression on cD8+cD28− T cells before and after in vitro cD8+ Treg generation.
Patient no. cD8+ Treg suppression  
(< or ≥25%)
cD127+/cD8+cD28− 
T cells at T0a (%)
cD127+/cD8+cD28− 
T cells at T7b (%)
cD39+/cD8+cD28− 
T cells at T0a (%)
cD39+/cD8+cD28−  
T cells at T7b (%)
1 ≥ 13 93 1 1.7
2 < 17 81 2 1.5
3 < 12 11 1 1.2
4 < 19 89 1.5 0.3
5 ≥ 33 29 0.6 0.8
6 ≥ 20 35 2.2 4.6
7 ≥ 40 36 2.2 2.4
10 ≥ 9.4 25 1.3 3
11 ≥ 27 2 0 0.5
12 ≥ 83 80 0.3 1
13 ≥ 80 85 0.3 1
14 ≥ 60 55 0 1
15 < 30 35 0.5 0
16 < 58 64 0.5 0
17 ≥ 60 50 1 1.4
18 ≥ 19 26 2 0.1
19 < 33 30 0.1 0.5
20 ≥ 82 78 0.1 1
21 ≥ 40 99 0 1
22 ≥ 15 10 0.1 1
23 ≥ 20 30 1 0.5
24 ≥ 40 30 0.5 1
25 ≥ 15 10 0 0.5
26 ≥ 20 15 0.5 1
27 < 15 35 0.5 0.1
28 < 19 22 1.6 0
29 < 27 25 1 0
30 < 25 20 0.7 0
aBaseline.
bAt the end of 7 days in vitro generation of CD8+ Treg.
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To further define if additional phenotypic abnormalities 
could be involved in functional alterations found in CD8+ 
Tregs generated from SSc patients, we analyzed the role of 
CD127. CD127, the IL-7 receptor α chain, is reportedly a useful 
marker for identifying memory and effector T cells, while its 
expression is down-modulated on CD4+CD25+ Treg cells (18, 
25, 26).
Similarly to what we observed for CD4+CD25+ Tregs, 
we previously demonstrated that maturation of circulating 
CD8+CD28− T cells to CD8+ Tregs is associated with CD127 
down-modulation (3). CD127 expression on CD8+CD28− cells 
from the peripheral blood of SSc patients was similar to what was 
observed in healthy controls. As expected, CD8+ Tregs generated 
from healthy donors displayed a down-modulation of CD127 
expression with respect to their circulating precursors. On the 
contrary, CD127 expression increased in CD8+ Tregs generated 
from SSc patients. Our observation is consistent with recent 
literature data indicating that IL-7 may play a significant role 
in numerous T cell-driven chronic inflammatory autoimmune 
diseases, and that this cytokine likely regulates the proliferation 
of autoreactive T cells (27).
Our data show for the first time that CD8+ Treg lymphocytes 
derived from SSc patients display a maturation defect that is char-
acterized by reduced CD39 expression associated with abnormal 
CD127 overexpression. Alterations of CD39 and CD127 expres-
sion could explain, at least partly, the functional defects observed 
in the CD8+ Tregs generated from patients affected by SSc.
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TaBle s1 | raw data of percent suppression activity by cD8+ Treg 
generated from 10 healthy donors.
TaBle s2 | raw data of percent suppression activity by cD8+ Treg 
generated from 28 ssc patients.
FigUre s1 | Percentage expression of cD39 (a) and cD127 (B) molecules 
on cD8+cD28+ T cells. Panel (a) also shows CD39 percentage expression on 
freshly isolated CD4+ Treg. T0: analyses performed on freshly purified cells; T7: 
analyses performed after 7 days incubation with IL2 and IL10 for CD8+ Treg 
generation. HC, healthy controls; SSc, systemic sclerosis patients.
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